ReviewAnti-cancer agents in medicinal chemistry2026
Aptamers in Osteosarcoma: New Paths for Diagnosis and Treatment.
Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteosarcoma remains the most common primary malignant bone tumor, with poor outcomes in metastatic or recurrent cases. Current treatments often fail to prevent relapse, highlighting the need for innovative therapeutic strategies. Aptamers, short and single-stranded oligonucleotides capable of folding into three-dimensional shapes, have emerged as promising tools for targeted cancer diagnostics and therapy due to their high affinity, specificity, and modifiability.
methodsA structured search was conducted through PubMed, Scopus, and Google Scholar up to March 2025, focusing on peer-reviewed articles exploring the use of aptamers in osteosarcoma. A total of 158 studies were included, highlighting aptamer applications in tumor diagnosis, pathway targeting, and precision drug delivery.
resultsAptamers demonstrated significant potential in osteosarcoma research, notably in identifying tumorigenesis pathways, enhancing diagnostic accuracy through ELISA and biosensors, and improving targeted drug delivery. SELEX-derived aptamers effectively targeted molecules such as CD133, EGFR, VEGFA, and FGFR1, leading to enhanced cytotoxicity, reduced off-target effects, and greater specificity for osteosarcoma cells and cancer stem cells. The integration of aptamers with nanoparticles further optimized therapeutic delivery, highlighting their capability to enhance precision medicine in osteosarcoma. DISCUSSION: Aptamers offer clear benefits over traditional osteosarcoma treatments. Their strong binding affinity to cancer cells, low risk of immune reactions, and flexible chemical modifications make them powerful tools for diagnosis and therapy, especially when combined with nanoparticle delivery systems.
conclusionAptamers represent a promising class of targeted agents for osteosarcoma. Future research should prioritize optimizing delivery strategies and validating clinical efficacy to accelerate their integration into clinical practice.
Indexed as
Identifiers
41820318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.